Clinical Trial

A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany

Recruiting
View on ClinicalTrials.gov →
Summary
This is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany. The study also seeks to address the existing data gap in the natural history and management of participants with ISM. The study is designed to follow each participant up to a maximum of 24 months.
Protocol Amendment History 1 change
notable Trial sites expanded: 4 -> 8 locations 2026-04-21
Trial Details
NCT Number NCT07255638
Lead Sponsor Blueprint Medicines Corporation
Conditions Indolent Systemic Mastocytosis
Enrollment 80 participants
Start Date 2025-12-09
Primary Completion 2028-12-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-20